EMA — authorised 22 August 2024
- Application: EMEA/H/C/005858
- Marketing authorisation holder: SIFI SPA
- Local brand name: Akantior
- Indication: Akantior is indicated for the treatment of Acanthamoeba keratitis in adults and children from 12 years of age.
- Pathway: orphan
- Status: approved
The European Medicines Agency (EMA) has approved Akantior, a medicine containing POLIHEXANIDE, for the treatment of Acanthamoeba keratitis. This rare eye infection is caused by a parasite and can lead to vision loss if left untreated. Akantior is indicated for adults and children aged 12 and above with this condition.